GILUPI CellCollector
home CellCollector about gilupi news contact
german version
Circulating tumor cells
Gilupi method
Practice and clinical validation
Special features
References
Interested
The GILUPI method: a revolutionary in vivo technology

1

Existing methods – in vitro   A revolutionary in vivo technology
ex vivo cellcollector gilupi

Current diagnostic approaches for the extraction of CTCs are in vitro methods with the inherent barrier of the small blood sample they depend on.
  in vivo cellcollector gilupi

The operating principle of the GILUPI CellCollector® is based on its innovative and patented design:

16 cm medical stainless steel wire (diameter 0,5 mm)
1 Rounded tip with 2 cm long layer of pure gold (carrier of a three-dimensional polymer functionalized layer) First Product generation Detector CANCER01
1 Functionalization through specific antibodies against cell surface antigens
(e.g. anti-EpCAM antibodies)

The GILUPI method overcomes the restrictions of a limited blood sample. While most diagnostic approaches today focus on maximizing the efficient exploitation of a blood sample, the GILUPI CellCollector® is designed to collect the targeted cells in vivo from the peripheral blood stream.

For more information (LINK)

During its 30 min in vivo application in a cubital arm vein, the GILUPI CellCollector® comes into contact with a large volume of the patient’s total blood volume. This is a significantly higher quantity of blood than found in blood samples using in vitro methods. Even at low concentrations of CTCs in the blood, the approach of the GILUPI CellCollector® increases the chances of isolating tumor cells – higher efficiency of CTC isolation.

2

1


The GILUPI CellCollector® is more specific and more efficient in the detection of EpCAM-positive CTCs than other existing in vitro methods. The EpCAM-positive tumor cells bind to anti-EpCAM-antibodies which are covalently attached to the GILUPI CellCollector® in vivo in the blood stream of a patient. The functionalized surface prevents the unspecific binding of other blood constituents – higher specificity of CTC isolation.

1

The GILUPI CellCollector® is available in two different product versions, Detektor CANCER01 (DC01) recommended for CTC enumeration and Detektor CANCER02 (DC02) recommended for further downstream analysis methods. Both products consist of a stainless steel wire, which has a functionalized surface at one end (gold and hydrogel coating with incorporated anti-EpCAM antibodies). The first generation product DC01 has a smooth, 2 cm long functionalized tip. The next generation product DC02 has a longer, 4 cm functionalized tip which consists of three thin twisted stainless steel wires for improved haemodynamic characteristics.


1
1
1st in vivo CTC isolation CE approval worldwide >>
1
Application possible in all cancer indications, clinical results available for prostate, lung, breast and colorectal cancer >>
1
Proven safety and functionality >>
1
70% CTC detection rate >>
1
CTC detection in all cancer stages >>
GILUPI presentations of clinical results at the following meetings & exhibitions:
DGU (Dresden)
ECCO (Amsterdam)
EAU (Stockholm)
ACTC (Athens)
ISMRC (Paris)
ASCO (Chicago)
EBCC (Vienna)
ELCC (Geneva)
DKK (Berlin)
MEDICA (Düsseldorf)